These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31502942)

  • 1. Variation in Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Outcomes in Asian American Men: A Multicenter Study.
    Gross MD; Marks LS; Sonn GA; Green DA; Wang GJ; Shoag JE; Cabezon E; Margolis DJ; Robinson BD; Hu JC
    J Urol; 2020 Mar; 203(3):530-536. PubMed ID: 31502942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance.
    Radtke JP; Kuru TH; Boxler S; Alt CD; Popeneciu IV; Huettenbrink C; Klein T; Steinemann S; Bergstraesser C; Roethke M; Roth W; Schlemmer HP; Hohenfellner M; Hadaschik BA
    J Urol; 2015 Jan; 193(1):87-94. PubMed ID: 25079939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy.
    Pepe P; Garufi A; Priolo GD; Galia A; Fraggetta F; Pennisi M
    J Urol; 2018 Oct; 200(4):774-778. PubMed ID: 29679618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma.
    Prendeville S; Gertner M; Maganti M; Pintilie M; Perlis N; Toi A; Evans AJ; Finelli A; van der Kwast TH; Ghai S
    J Urol; 2018 Jul; 200(1):104-113. PubMed ID: 29408568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
    Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
    Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
    van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO
    Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort-How Many Clinically Significant Prostate Cancers are Missed?
    Feuer Z; Meng X; Rosenkrantz AB; Kasivisvanathan V; Moore CM; Huang R; Deng FM; Lepor H; Wysock JS; Huang WC; Taneja SS
    J Urol; 2021 Mar; 205(3):740-747. PubMed ID: 33026927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of Prostate Imaging Reporting and Data System Version 2 for the Detection of Prostate Cancer.
    Hofbauer SL; Maxeiner A; Kittner B; Heckmann R; Reimann M; Wiemer L; Asbach P; Haas M; Penzkofer T; Stephan C; Friedersdorff F; Fuller F; Miller K; Cash H
    J Urol; 2018 Oct; 200(4):767-773. PubMed ID: 29733838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Institutional Learning Curve of Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy: Temporal Improvements in Cancer Detection in 4 Years.
    Meng X; Rosenkrantz AB; Huang R; Deng FM; Wysock JS; Bjurlin MA; Huang WC; Lepor H; Taneja SS
    J Urol; 2018 Nov; 200(5):1022-1029. PubMed ID: 29886090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance.
    Ma TM; Tosoian JJ; Schaeffer EM; Landis P; Wolf S; Macura KJ; Epstein JI; Mamawala M; Carter HB
    Eur Urol; 2017 Feb; 71(2):174-180. PubMed ID: 27236496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anterior Localization of Prostate Cancer Suspicious Lesions in 1,161 Patients Undergoing Magnetic Resonance Imaging/Ultrasound Fusion Guided Targeted Biopsies.
    Leyh-Bannurah SR; Kachanov M; Beyersdorff D; Preisser F; Tilki D; Fisch M; Graefen M; Budäus L
    J Urol; 2018 Nov; 200(5):1035-1040. PubMed ID: 29935274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
    Meng X; Rosenkrantz AB; Mendhiratta N; Fenstermaker M; Huang R; Wysock JS; Bjurlin MA; Marshall S; Deng FM; Zhou M; Melamed J; Huang WC; Lepor H; Taneja SS
    Eur Urol; 2016 Mar; 69(3):512-7. PubMed ID: 26112001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Race and prostate imaging: implications for targeted biopsy and image-based prostate cancer interventions.
    Gross MD; Al Hussein Al Awamlh B; Shoag JE; Mauer E; Banerjee S; Margolis DJ; Mosquera JM; Hamilton AS; Schumura MJ; Hu JC
    BMJ Surg Interv Health Technol; 2019; 1(1):e000010. PubMed ID: 35047774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple Regions of Interest on Multiparametric Magnetic Resonance Imaging are Not Associated with Increased Detection of Clinically Significant Prostate Cancer on Fusion Biopsy.
    Patel N; Halpern JA; Kasabwala K; Cricco-Lizza E; Herman M; Margolis D; Xu C; Robinson BD; Wang Y; McClure T; Hu JC
    J Urol; 2018 Sep; 200(3):559-563. PubMed ID: 29518433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification.
    Mendhiratta N; Rosenkrantz AB; Meng X; Wysock JS; Fenstermaker M; Huang R; Deng FM; Melamed J; Zhou M; Huang WC; Lepor H; Taneja SS
    J Urol; 2015 Dec; 194(6):1601-6. PubMed ID: 26100327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection.
    Mertan FV; Greer MD; Shih JH; George AK; Kongnyuy M; Muthigi A; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    J Urol; 2016 Sep; 196(3):690-6. PubMed ID: 27101772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is targeted magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy enough for the detection of prostate cancer in patients with PI-RADS ≥3: Results of a prospective, randomized clinical trial.
    Zhang J; Zhu A; Sun D; Guo S; Zhang H; Liu S; Fu Q; Zhang K
    J Cancer Res Ther; 2020; 16(7):1698-1702. PubMed ID: 33565519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.